CF Timeline


First comprehensive medical report on CF was written by Dorothy Andersen, M.D.


During a NYC heat wave, Dr. Paul di Sant’Agnese and others connect the extra loss of salt by CF patients to the underlying cellular problem


The Cystic Fibrosis Foundation becomes the National CF Research Foundation and awards the first research grants to Dr. Dorothy Andersen, Dr. Paul di Sant’Agnese, and Dr. Harry Schwachman


The Foundation establishes the accredited care center network, creating 2 care centers devoted to treating CF


30 Foundation-accredited care centers are in operation


The first basic science committee is established to investigate CF at the cellular level and find answers


More than 100 Foundation-accredited care centers are in operation


The Research Development Program, a network of research centers and universities and medical schools nationwide, is established


A group of Foundation-supported scientists find the defective CF gene and its protein product, CFTR


The FDA approves Pulmozyme, a drug that is proven to thin the mucus in the lungs and is the first drug developed specifically for CF


The FDA approves tobramycin, or TOBI, which is the first aerosol antibiotic designed for CF, that was proven to reduce the amount of time a CF patient is in the hospital and improves their lung functi


Foundation-supported scientists map the entire genetic structure of the most common cause of CF lung infections, a bacteria called Pseudomonas aeruginosa


Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a nonprofit research affiliate of the Foundation, is established to govern drug discovery and development efforts


CFFT-supported studies in Australia and at the University of North Carolina show that inhaled hypertonic saline helps clear CF mucus and improve lung health, so it becomes a therapeutic option


Ivacaftor, an oral drug that targets the faulty CFTR protein, enters clinical trials with the hopes of opening chloride channels that don’t function correctly


Phase 2 studies of Ivacaftor show improvements in the key signs of the disease, and the studies achieve “proof of concept” that it is possible to treat the key signs of CF


FDA approves a new antibiotic, Cayston, an inhaled solution that treats lung infections for people with CF who battle infections and develop a resistance to existing antibiotics


4 more drugs are approved to fight CF

2012 - 2016

The Foundation is still maintaining potential therapies targeting CF in a "pipeline". The more drugs in the pipeline, the greater the odds of producing successful therapies and a cure for CF

2017 - Present